Recombinant interferon beta phase I-II trial children recurrent brain tumors multicenter phase I-II trial intravenous IV human recombinant interferon beta rIFN-beta Betaseron Triton Bioscience Inc Almeda CA children recurrent progressive primary brain spinal cord tumors total patients high-grade astrocytoma brainstem glioma primitive neuroectadermal tumor germ cell spinal cord astrocytoma Betaseron IV infusion minutes times week Monday-Wednesday-Friday MWF dose levels patients dose level treatment plan three-step dose escalation patient weeks initiation phase dose-escalation schema dose levels Patients objective response stable disease weeks maintenance phase final dose ie MWF Common transient effects chills fever fatigue Dose-limiting toxicities hematologic hepatic CNS maintenance maximum-tolerable dose MTD ie dose level Response completion initiation phase intervals maintenance phase Objective partial responses patients high-grade astrocytoma brain-stem glioma assessable patients partial responses median months patients stable disease median months Antineoplastic activity children high-grade astrocytomas brainstem gliomas dose-intensive regimen 